B-cell acute lymphoblastic leukemia (B-ALL) is the most common cancer in children, accounting for around 85% of pediatric ...

This study identifies 53BP1 as an interaction partner of GMCL1 (a likely CUL3 substrate receptor). The study seeks to link this finding to regulation of the mitotic surveillance pathway and paclitaxel ...

Study in mice shows how a host-elicited factor benefits gut immunological homeostasis by selectively targeting commensal ceramide molecules.

Chimeric antigen receptor (CAR) T cells targeting CD19 have transformed the treatment of B-cell cancers, but many patients do not have long-term remission. We designed an anti-CD19 enhanced ...

When it comes to getting the most out of a vaccine, arm consistency can make a difference. Some studies suggest that getting a booster in the same arm as the initial shot can boost the immune system’s ...

Clinical data on a CD19-directed CAR-T cell therapy in lupus has sent interest in the depletion of B cells to treat autoimmune and inflammatory diseases into overdrive in recent years. Companies ...

A promising lead has emerged from examining the interaction between the tumor and immune cells, including CAR-T cells. It turns out that B-ALL tumors may take advantage of the body’s natural ...

“We believe this treatment is so effective because the B cells play a key role in driving the disease pathogenesis, both by activating harmful T cells and by directly secreting cytokines that ...

Cemacabtagene ansegedleucel, an allogeneic chimeric antigen receptor (CAR) T-cell therapy, is being investigated in relapsed/refractory large B-cell lymphoma. The investigational allogeneic ...

So the question being posed here in this sub-analysis from ELM-1 is the activity of odronextamab as monotherapy in the treatment of diffuse large B-cell lymphoma relapsing after CAR T-cell therapy.

trials of allogeneic chimeric antigen receptor T-cell therapy (CAR T) in relapsed/refractory large B-cell lymphoma (LBCL), explains why this hematologic cancer is such an attractive target for CAR ...

A “complete eradication” of B cells with chimeric antigen receptor T-cell therapy is responsible for the long-term, drug-free remission from autoimmune diseases observed after treatment ...